Eli Lilly (LLY)

On Oct. 14, 2026, a hotter-than-expected CPI report pressures growth stocks and the semiconductor selloff continues.

It's banking on winners continuing to run.

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ...

Kura Oncology (NASDAQ:KURA) and its newly formed affiliate Caspian Therapeutics outlined plans to develop KO-7246, an oral menin inhibitor, for diabetes, citing preclinical data that the companies said showed beta-cell expansion, improved glucose control and sustained effects after treatment ended.

Bristol Myers Squibb recovered to $7.1B in net income while Eli Lilly more than doubled profits to $20.6B, a stark contrast in momentum that reshapes the value-versus-growth debate.

These stocks have rewarded their shareholders with significant dividend increases in recent years and are likely to continue doing so in the future.

FHLC offers broader sector exposure at a 0.08% expense ratio, compared with IBB's concentrated biotech focus at 0.44%, but IBB delivered stronger 1-year returns despite higher volatility.

Eli Lilly's next big growth driver could be bigger than Zepbound.

This pharma stock has climbed in the triple digits in recent years.

Eli Lilly's stock price is comfortably above $1,000, and management could easily justify doing a stock split.

AbbVie trades at a 40% valuation discount but faces revenue concentration risk, while Eli Lilly's cardiometabolic dominance commands a premium.

Two healthcare stocks that are leading their niches, and two that investors aren't giving enough credit to in the same niches.

What Happened? Shares of biotech company Biogen (NASDAQ:BIIB) jumped 3.5% in the pre-market session after JPMorgan upgraded the stock to Overweight from Neut...

Eli Lilly isn't content with the success of its current GLP-1 drugs; it's on the hunt for even better weight loss solutions.

Major index funds are heavily concentrated with the same few tech names. How can investors avoid overlapping stocks?

Oppenheimer raised Viking Therapeutics' price target to $120, citing strong trial data, and an improving probability of success for its key drug.

Lilly's recent retreat isn't a sign of a broken investment thesis.

The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant ch...

Pharmaceutical stocks have been one of the best places to invest over the past year. Choosing between these two funds is really a question about how you want to own what comes next.

IBB has delivered stronger returns than IYH but with dramatically sharper swings in both directions. Here is how to decide which trade-off fits your portfolio.

One offers broad diversification at 0.08% cost, while the other targets concentrated biotech growth with higher volatility.

These elite businesses could help you build lasting wealth.

The weight-loss drugs are growing in popularity and altering consumer behavior in significant ways.

IHE concentrates 23.6% in Eli Lilly and delivers 1.4% yield, while XPH spreads risk across 62 holdings with a lower 0.35% expense ratio.